A Hepatic Impairment Study for PF-04965842

This is a Phase 1 non randomized, open label, single dose, parallel cohort, multisite study
to investigate the effect of renal impairment on the pharmacokinetics, safety and
tolerability of PF-04965842 after a single 200 mg oral dose. Subjects will be selected and
categorized into normal renal function or renal impairment groups based on their estimated
glomerular filtration rate. Part 1: A total of approximately16 subjects will be enrolled;
approximately 8 subjects with severe renal impairment and approximately 8 with normal renal
function. After statistical evaluation of results from Part 1, Part 2 may be conducted and
approximately 8 subjects each with moderate and mild renal impairment will be enrolled. The
total duration of participation from the Screening Visit to Day 4 will be a maximum of 31
days and from the Screening Visit to Follow-up Contact/Visit will be a maximum of 67 days.

Inclusion Criteria:

- Breath alcohol test at Screening and Day -1 must be negative.

- Body mass index (BMI) of ≥ 17.5 to ≤ 40.0 kg/m2; and a total body weight >50 kg (110
lb).

Additional inclusion criteria for subjects with renal impairment:

- Meet the following eGFR criteria during the screening period based on the MDRD
equation:

- Severe renal impairment: eGFR <30 mL/min, but not requiring hemodialysis.

- Moderate renal impairment (Part 2 only): eGFR ≥30 mL/min and <60 mL/min.

- Mild renal impairment (Part 2 only): eGFR between 60 and 89 mL/min.

- Any form of renal impairment except acute nephritic syndrome (subjects with history of
previous nephritic syndrome but in remission can be included).

- Stable concomitant drug regimen.

Exclusion Criteria:

- Renal transplant recipients.

- Urinary incontinence without catheterization.

- Subjects with clinically significant infections within the past 3 months (for example,
those requiring hospitalization, or as judged by the Investigator), evidence of any
infection (including influenza) within the past 7 days, history of disseminated herpes
simplex infection or recurrent or disseminated herpes zoster.

- Subjects with a malignancy or with a history of malignancy, with the exception of
adequately treated or excised non-metastatic basal cell or squamous cell cancer of the
skin or cervical carcinoma in situ.

- History of or current positive results for human immunodeficiency virus, Hepatitis B,
Hepatitis C.

Additional exclusion criteria for subjects with renal impairment:

- Subjects requiring hemodialysis and peritoneal dialysis.

- Screening BP ≥ 180 mm Hg (systolic) or ≥ 110 mm Hg (diastolic).

- Screening supine 12-lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec.